1257MO ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (Pts) with advanced EGFR wildtype (WT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase I study

作者：M. De Miguel, Noboru Yamamoto, Judith Raimbourg, B.C. Cho, M. Gottfried, S.M. Stemmer, J.W. Goldman, Martha Blaney, Theodore S. Jennaro, Athanasios Vasilopoulos, R.R. Li, Kevin J. Freise, Martha Raluca Neagu Aristide, G. Morrison-Thiele, Z.N. Hunter, Michael C. Burns, D. Ross Camidge · 发表于：Annals of Oncology · 年份：2024 · DOI：10.1016/j.annonc.2024.08.1314 · 被引用次数：12 · 研究领域：Lung Cancer Treatments and Mutations、HER2/EGFR in Cancer Research、Radiomics and Machine Learning in Medical Imaging